InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
35 hedge funds and large institutions have $66.6M invested in InVivo Therapeutics Holdings Corp in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
67% less call options, than puts
Call options by funds: $280K | Put options by funds: $838K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WF
Welch & Forbes
Boston,
Massachusetts
|
+$10.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.78M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$4.49M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.7M |
Top Sellers
NVIV Hedge Fund Activity: Q2 2015 in Review
35 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2015, worth a combined $66.6M.
Buyers outnumbered sellers: 35 funds opened new NVIV positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Welch & Forbes, opening a new position worth an estimated $10.8M.
- 35 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $66.6M of InVivo Therapeutics Holdings Corp stock for Q2 2015.
- 35 funds opened new InVivo Therapeutics Holdings Corp positions in Q2 2015 and 0 closed out, a net change of +35 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q2 2015 was Welch & Forbes, an estimated $10.8M added.
Based on aggregated 13F filings for Q2 2015.